Masaki Nagashima

Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer

Makoto Nishio, Atsushi Horiike, Haruyasu Murakami et al. · Lung Cancer · 2015 · 39 citations · Full text

Risk Factors for Lumbar Disc Degeneration in High School American Football Players

Masaki Nagashima, Hitoshi Abe, Kenji AMAYA et al. · The American Journal of Sports Medicine · 2013 · 30 citations

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports

Noritoshi Yoshii, Tadamichi Suzuki, Masaki Nagashima et al. · Anti-Cancer Drugs · 2011 · 25 citations

Antifibrotic Therapy, Death Rate, Inflammatory Lung Disease +11

Synthesis and Cavity Size Effect of Pd-Containing Macrocycle Catalyst for Efficient Intramolecular Hydroamination of Allylurethane

Masahiro Ogawa, Masaki Nagashima, Hiromitsu Sogawa et al. · Organic Letters · 2015 · 17 citations

Asymmetric Catalysis, Chemical Engineering, Cross-coupling Reaction +13

A method for quantifying intervertebral disc signal intensity on T2-weighted imaging

Masaki Nagashima, Hitoshi Abe, Kenji AMAYA et al. · Acta Radiologica · 2012 · 16 citations